タナカ ジユンジ   TANAKA Junji
  田中 淳司
   所属   医学部 医学科(東京女子医科大学病院)
   職種   教授・基幹分野長
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
掲載誌名 正式名:Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
略  称:Biol Blood Marrow Transplant
ISSNコード:15236536/10838791
掲載区分国外
巻・号・頁 25(8),pp.1597-1602
著者・共著者 Hangai Mayumi†, Urayama Kevin Y, Tanaka Junji, Kato Koji, Nishiwaki Satoshi, Koh Katsuyoshi, Noguchi Maiko, Kato Keisuke, Yoshida Nao, Sato Maho, Goto Hiroaki, Yuza Yuki, Hashii Yoshiko, Atsuta Yoshiko, Mizuta Shuichi, Kato Motohiro
発行年月 2019/08
概要 Hematologic stem cell transplantation (HSCT) is the most potent consolidation therapy for high-risk acute lymphoblastic leukemia (ALL), but their outcomes and complications in adolescent and young adult (AYA) patients remain unclear. We compared outcomes after HSCT for ALL among children (age 1 to 9 years; n = 607), adolescents (age 10 to 19 years; n = 783), and young adults (age 20 to 29 years old, n = 603), based on Japanese nationwide registry data. The 5-year overall survival (OS) rate among AYA patients was worse than that of children, at 64% (95% confidence interval [CI], 60% to 68%). In the AYA, the 5-year treatment-related mortality (TRM) after HSCT was 19% (95% CI, 16% to 22%), significantly higher than that in younger patients. The most common cause of TRM in the AYA was infection. The relapse rate was not different across the 3 age groups. When focusing on older adolescents (age 15 to 19 years), there was no difference in outcomes between those treated in pediatric centers and those treated in adult centers. In conclusion, the AYA had a greater risk of nonrelapse death than younger patients, and infection was the most common cause. Further optimization is required for HSCT in AYAs with ALL.
DOI 10.1016/j.bbmt.2019.04.014
PMID 31002992